Amgen (AMGN) vs argenx (ARGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amgen (AMGN) has outperformed argenx (ARGX) over the past year, gaining 39.8% versus a gain of 16.4%. Over five years, ARGX leads with a +216.1% price change compared with +98.7% for AMGN. Amgen is the larger company by market cap ($223.32 billion vs $57.74 billion), about 3.9 times the size.
On valuation, Amgen trades at a lower forward P/E (16.9x vs 26.7x for argenx). Amgen pays a dividend yielding 2.37%, while argenx does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | ARGX |
|---|---|---|
| Share price | $413.08 | $928.44 |
| Market cap | $223.32B | $57.74B |
| 1-day change | +2.60% | -0.22% |
| YTD return | +26.20% | +10.40% |
| 1-year return | +39.77% | +16.44% |
| 5-year return | +98.75% | +216.08% |
| P/E ratio (TTM) | 25.00 | 35.42 |
| Forward P/E | 16.88 | 26.74 |
| EPS (TTM) | $16.52 | $26.21 |
| Dividend yield | 2.37% | 0.00% |
| Annual dividend | $9.80 | $0.00 |
| Revenue (latest FY) | $36.75B | — |
| Revenue growth (YoY) | +9.95% | — |
| Net income (latest FY) | $7.71B | $1.29B |
| Gross margin | 67.25% | — |
| Operating margin | 24.71% | — |
| Net margin | 20.98% | — |
| 52-week high | $447.03 | $1,072.75 |
| 52-week low | $288.00 | $661.85 |
| Distance from 52-week high | -7.59% | -13.45% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -5.23% | +27.12% |
| Average volume | 2.72M | 283.80K |
| Shares outstanding | 540.63M | 62.19M |
| Employees | 31,500 | 1,863 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 3.9 times larger than argenx by market value ($223.32B vs $57.74B).
- AMGN has outperformed ARGX by 23.3 percentage points over the past year.
- argenx trades at a higher earnings multiple (35.4x vs 25.0x trailing P/E).
- Amgen offers a meaningfully higher dividend yield (2.37% vs 0.00%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
AMGN vs ARGX FAQ
Which is bigger, Amgen or argenx?
Amgen (AMGN) is larger, with a market capitalization of $223.32B compared with $57.74B for argenx (ARGX).
Which stock has performed better over the past year, AMGN or ARGX?
AMGN returned +39.77% over the past 12 months, compared with +16.44% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or ARGX?
AMGN has the lower trailing P/E at 25.0, versus 35.4 for ARGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or argenx?
Amgen pays a dividend yielding 2.37%, while argenx does not currently pay a regular dividend.
Are Amgen and argenx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.